Results 41 to 50 of about 12,265 (153)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment

BMJ Open Ophthalmology, 2023
Topic This systematic review and meta-analysis provides a summary of the efficacy and safety of ranibizumab biosimilars relative to reference ranibizumab anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related ...
Netan Choudhry, Amin Hatamnejad, Rohan Dadak, Samantha Orr, Charles Wykoff   +4 more
doaj   +1 more source

Optimization of antibody binding by adjusting thermodynamic stability during the maturation of antibody affinities

Protein Science, Volume 35, Issue 9, September 2026.
Abstract Somatic mutations and antibody clone selection occur in B‐cell hyper‐evolution over extremely brief periods of time. Herein, we developed a technique for antibody screening by immunizing alpacas with antigens and observing antibody sequence transitions over time, a method we named Tracking the Evolution of Antibodies over time.
Yoko Akazawa‐Ogawa, Tomonari Matsuda, Norihiko Kiyose, Nobuo Miyazaki, Tetsuo Fukuta, Motoyasu Adachi, Yuji Ito, Yoshihisa Hagihara   +7 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Implantable drug delivery system: Frontiers of medicine‐engineering interdisciplinary

Interdisciplinary Medicine, Volume 4, Issue 4, July 2026.
This review systematically summarizes the driving mechanisms of implantable on‐demand drug delivery systems (IDDS), including endogenous, exogenous, and closed‐loop strategies. It highlights the pivotal roles of flexible electronics and miniaturization in enhancing the tissue conformity and spatial adaptability.
Yu Zeng, Rongtai Su, Manyu Zhao, Xin Song, Ran Liu, Yuhao Zhou, Chaojuan Yang, Yanli Jiao, Xiao‐Wei Xiang, Lingqian Chang   +9 more
wiley   +1 more source

Evaluation of efficacy dexamethasone intravitreal implant compared to treatment with anti-VEGF in the treatment of diabetic macular edema

Senses and Sciences, 2014
Objective: The study compares the effectiveness of an intravitreal slow-release dexamethasone implant respect to an intravitreal injection of a anti-VEGF, ranibizumab, in the treatment of diabetic macular edema (DME).
Elena Pacella, Giuseppe La Torre, Paolo Turchetti, Concetta Merisola, Tommaso Lenzi, Francesco Mazzeo, Pietro Luchetti, Silvia Casale, Fernanda Pacella   +8 more
doaj   +1 more source

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

Journal of Diabetes Investigation, Volume 17, Issue 7, Page 1120-1131, July 2026.
Combining oral sodium‐glucose cotransporter 2 inhibitors with reduced intravitreal injections of anti‐vascular endothelial growth factor showed potential efficacy for mild diabetic macular edema. ABSTRACT Aims To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular
Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote   +6 more
wiley   +1 more source

Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells

FEBS Open Bio, Volume 16, Issue 6, Page 1150-1165, June 2026.
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi, Zainab Quraishi, Shima Khezri Azizi Far, Madaleine Ward, Aidan Conway, Reem Abdulredha, Eman Mshari, Yousif A. Shamsaldeen   +7 more
wiley   +1 more source

Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies

Advanced Healthcare Materials, Volume 15, Issue 23, 19 June 2026.
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best, Gizem Karabiyik, Gerd Geerling, Sarah Barbara Zwingelberg, Gregor Lang, Martin Humenik   +5 more
wiley   +1 more source

Treatment of age-related macular degeneration: focus on ranibizumab

Clinical Ophthalmology, 2008
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A ...
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter Szurman   +4 more
doaj